FFAR1 and type 2 diabetes mellitus: In 2010, fasiglifam was reported as the first drug to selectively stimulate GPR40 and significantly improve glycemic control, making it a promising candidate drug for patients with type 2 diabetes (Tsujihata et al., 2011).